Immatics N.V. (IMTX) stock
IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.29+0.12 (+1.94%)
Close on Nov 17, 2026Market cap $843.31MP/E –Yield –
Immatics cash
Cash and short-term investments held at the end of each period.
Immatics's cash was €232.46M at Jun 30, 2026. For fiscal 2025 it was €345.92M, up 46.1% from the year before. The highest annual figure on record is €345.92M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €345.92M | +46.1% |
| FY2024 | Dec 31, 2024 | €236.75M | +8.4% |
| FY2023 | Dec 31, 2023 | €218.47M | +47.1% |
| FY2022 | Dec 31, 2022 | €148.52M | +11.7% |
| FY2021 | Dec 31, 2021 | €132.99M | -35.9% |
| FY2020 | Dec 31, 2020 | €207.53M | +100.8% |
| FY2019 | Dec 31, 2019 | €103.35M | +162.5% |
| FY2018 | Dec 31, 2018 | €39.37M | +367.8% |
| FY2017 | Dec 31, 2017 | €8.42M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €232.46M | +22.9% |
| Q4 FY2025 | Dec 31, 2025 | €345.92M | +118.7% |
| Q2 FY2025 | Jun 30, 2025 | €256.64M | +110.2% |
| Q4 FY2024 | Dec 31, 2024 | €236.75M | +8.4% |
| Q3 FY2024 | Sep 30, 2024 | €189.20M | +45.1% |
| Q2 FY2024 | Jun 30, 2024 | €158.14M | +6.5% |
| Q1 FY2024 | Mar 31, 2024 | €122.09M | -53.9% |
| Q4 FY2023 | Dec 31, 2023 | €218.47M | +64.3% |
| Q2 FY2023 | Jun 30, 2023 | €130.41M | -18.5% |
| Q4 FY2022 | Dec 31, 2022 | €148.52M | -28.4% |
| Q2 FY2022 | Jun 30, 2022 | €265.13M | +208.1% |
| Q4 FY2021 | Dec 31, 2021 | €132.99M | +28.7% |
| Q2 FY2021 | Jun 30, 2021 | €160.09M | +306.7% |
| Q4 FY2020 | Dec 31, 2020 | €207.53M | +2366.2% |
| Q2 FY2020 | Jun 30, 2020 | €86.06M | – |
| Q4 FY2019 | Dec 31, 2019 | €103.35M | – |
| Q4 FY2018 | Dec 31, 2018 | €39.37M | – |
| Q4 FY2017 | Dec 31, 2017 | €8.42M | – |
See a number that looks wrong?